Mucosal fenestration is a rare entity wherein apex of the tooth is exposed in the oral cavity due to breakdown of the overlying bone and mucosa. This leads to accumulation of plaque and if left untreated can hamper the further prognosis of the tooth. Although there are few evidences regarding mucosal fenestrations in posterior region of maxilla, treatment of the same have been challenging for the clinicians. This case report describes the management of mucosal fenestrations in the posterior maxilla by regenerative periodontal flap surgical approach using xenograft (Osseograft) and platelet-rich fibrin membrane.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041070 | PMC |
| http://dx.doi.org/10.4103/jisp.jisp_224_19 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
Breast Cancer Res
January 2025
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Background: CDK4/6 inhibitors have significantly improved the survival of patients with HR-positive/HER2-negative breast cancer, becoming a first-line treatment option. However, the development of resistance to these inhibitors is inevitable. To address this challenge, novel strategies are required to overcome resistance, necessitating a deeper understanding of its mechanisms.
View Article and Find Full Text PDFSemi-mechanistic efficacy model for PARP + ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs.
Br J Cancer
January 2025
Physiomics PLC, Abingdon, UK.
Background: Promising cancer treatments, such as DDR inhibitors, are often challenged by the heterogeneity of responses in clinical trials. The present work aimed to build a computational framework to address those challenges.
Methods: A semi-mechanistic pharmacokinetic-pharmacodynamic model of tumour growth inhibition was developed to investigate the efficacy of PARP and ATR inhibitors as monotherapies, and in combination.
An IgM Cleaving Enzyme for Clearance of Anti-Pig Xenoreactive Antibodies in a Nonhuman Primate Model.
Xenotransplantation
January 2025
Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
Background: The removal of preformed antibodies with cleaving enzyme like IdeS (Imlifidase) has demonstrated therapeutic potential in organ transplantation for sensitized recipients. However, preformed xenoreactive antibodies (XAbs) against porcine glycans are predominantly IgM and considered detrimental in pig-to-human xenotransplantation.
Methods: Recombinant IceM, an endopeptidase cleaving IgM, was generated in Escherichia coli.
LIG1 is a synthetic lethal target in BRCA1 mutant cancers.
Mol Cancer Ther
January 2025
Tango Therapeutics (United States), Boston, United States.
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on poly(ADP-ribose) polymerase (PARP) inhibitors, which are subject to high rates of innate or acquired resistance in patients. Here, we used CRISPR/Cas9-based screening to identify DNA Ligase I (LIG1) as a novel target for synthetic lethality in BRCA1-mutated cancers. Publicly available data supported LIG1 hyperdependence of BRCA1-mutant cells across a variety of breast and ovarian cancer cell lines.
View Article and Find Full Text PDFA BiO-Optimizing Site Targeted (BOOST) Approach to Periodontal Regeneration Through Local Doxycycline Prior to Surgery: A Randomized Clinical Trial.
J Periodontal Res
January 2025
Department of Surgical Sciences, C.I.R. Dental School, University of Turin, Turin, Italy.
Aim: To test a BiO-Optimizing Site Targeted (BOOST) approach to periodontal regeneration by the adjunctive use of locally delivered doxycycline (DOX) 2 weeks prior to minimally invasive surgery in terms of clinical and radiographic outcomes at 1 year.
Methods: For this randomized clinical trial, stage III/IV periodontitis patients presenting sites with intrabony defects and bleeding on probing (BoP+) after steps 1-2 of periodontal treatment were included. Sites were treated via subgingival instrumentation with or without a BOOST approach by local DOX.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!